Oral cancer prevention and the evolution of molecular-targeted drug development
- PMID: 15637397
- DOI: 10.1200/JCO.2005.09.128
Oral cancer prevention and the evolution of molecular-targeted drug development
Abstract
The multifaceted rationale for molecular-targeted prevention of oral cancer is strong. Oral cancer is a major global threat to public health, causing great morbidity and mortality rates that have not improved in decades. Oral cancer development is a tobacco-related multistep and multifocal process involving field carcinogenesis and intraepithelial clonal spread. Biomarkers of genomic instability, such as aneuploidy and allelic imbalance, can accurately measure the cancer risk of oral premalignant lesions, or intraepithelial neoplasia (IEN). Retinoid-oral IEN studies (eg, of retinoic acid receptor-beta, p53, genetic instability, loss of heterozygosity, and cyclin D1) have advanced the overall understanding of the biology of intraepithelial carcinogenesis and of preventive agent molecular mechanisms and targets-important advances for monitoring preventive interventions and assessing cancer risk and pharmacogenomics. Clinical management of oral IEN varies from watchful waiting to complete resection, although complete resection does not prevent oral cancer in high-risk patients. New approaches, such as interventions with molecular-targeted agents and agent combinations in molecularly defined high-risk oral IEN patients, are urgently needed to reduce the devastating worldwide consequences of oral cancer.
Similar articles
-
[Model program for screening oral cancers in the Roma population].Magy Onkol. 2007;51(2):95-101. Epub 2007 Jul 29. Magy Onkol. 2007. PMID: 17660865 Hungarian.
-
The convergent development of molecular-targeted drugs for cancer treatment and prevention.Clin Cancer Res. 2007 Jul 15;13(14):4035-41. doi: 10.1158/1078-0432.CCR-07-0063. Clin Cancer Res. 2007. PMID: 17634526 Review.
-
Disease mechanism and biomarkers of oral squamous cell carcinoma.Curr Opin Oncol. 2006 May;18(3):228-33. doi: 10.1097/01.cco.0000219250.15041.f8. Curr Opin Oncol. 2006. PMID: 16552233 Review.
-
Novel management of oral cancer: a paradigm of predictive oncology.Clin Med Res. 2004 Nov;2(4):233-42. doi: 10.3121/cmr.2.4.233. Clin Med Res. 2004. Retraction in: Clin Med Res. 2007 Oct;5(3):203. doi: 10.3121/cmr.2004.587.retraction. PMID: 15931363 Free PMC article. Retracted. Review.
-
The evolution of predictive oncology and molecular-based therapy for oral cancer prevention.Int J Cancer. 2005 Jun 20;115(3):339-45. doi: 10.1002/ijc.20896. Int J Cancer. 2005. PMID: 15688375 Review.
Cited by
-
Review Insights on Salivary Proteomics Biomarkers in Oral Cancer Detection and Diagnosis.Molecules. 2023 Jul 7;28(13):5283. doi: 10.3390/molecules28135283. Molecules. 2023. PMID: 37446943 Free PMC article. Review.
-
Expression of stathmin in oral squamous cell carcinoma and its correlation with tumour proliferation.J Oral Maxillofac Pathol. 2023 Jan-Mar;27(1):103-108. doi: 10.4103/jomfp.jomfp_202_22. Epub 2023 Mar 21. J Oral Maxillofac Pathol. 2023. PMID: 37234316 Free PMC article.
-
The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy.Front Oncol. 2023 Jan 19;12:1067974. doi: 10.3389/fonc.2022.1067974. eCollection 2022. Front Oncol. 2023. PMID: 36793341 Free PMC article. Review.
-
Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.Int J Nanomedicine. 2022 Sep 15;17:4293-4306. doi: 10.2147/IJN.S377816. eCollection 2022. Int J Nanomedicine. 2022. PMID: 36134201 Free PMC article. Review.
-
Unmet Needs and Perspectives in Oral Cancer Prevention.Cancers (Basel). 2022 Apr 2;14(7):1815. doi: 10.3390/cancers14071815. Cancers (Basel). 2022. PMID: 35406587 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
